Skip to main content

Please note that this is a beta version of our website. Should you encounter any bugs, glitches, lack of functionality or other problems on the website, please let us know immediately so we can rectify these accordingly. Your help in this regard is greatly appreciated! You can email us.

Login to North West London Pathology – consumables service

If you need a new account or you have a query about your order, please telephone the pathology call centre on 0203 313 5353.

If you have forgotten your password you can reset this yourself. Please click here if you have forgotten your password.

Results Line and Enquiries

0203 313 5353

Placental alkaline phosphatase (PLAP)

Category Biochemistry >> Oncology
Test background

Alkaline phosphatases (ALP) are membrane anchored dimeric enzymes. Specific phospholipases can cleave membrane bound ALP and produce free ALP in the serum. ALP consists of a family of four isoenzymes: (1) placental ALP (PLAP) (2) germ cell ALP (PLAP-like), (3) intestinal ALP (IAP), and (4) nonspecific tissue ALP (TNAP, also known as liver/bone/kidney ALP). The PLAP and PLAP-like enzymes share 98 % homology in their amino acid sequence and are both recognised by the PLAP assay. PLAP is synthesised in the placental syncytiotrophoblast starting after the 12th week of pregnancy. The PLAP-like enzyme is primarily synthesised in the testis, cervix and thymus. In healthy non-smoking adults, PLAP/PLAP-like enzyme activity represents less than 1 % of all serum ALP. Smoking causes elevation of the serum concentrations of the PLAP-like enzyme, limiting the value of PLAP-like enzyme as a tumour marker in smokers. Serum concentrations of PLAP-like enzyme return to the normal range after 1-2 months of smoking cessation. Ectopic expression of PLAP has been associated with cancer of the ovary, testis, lung and colorectal tract. The highest frequency of serum elevations of PLAP and PLAP-like enzyme are found in patients with ovarian (25 %-65.5 %) and testicular neoplasms 22 %-89 % (20-90 %).

Clinicial Indications

Germ cell tumour

Diagnosis:PLAP may be helpful as an adjunctive test in the clinical work-up of GCT. It is most frequently raised in seminomas.
Treatment monitoring: in PLAP-positive disease, increasing levels may indicate progression and/or treatment resistance, while declining levels may indicate responsiveness and recovery.
Surveillance: several studies have shown that if PLAP is used in combination with established markers, a greater sensitivity for relapse detection can be achieved. Specificity is impaired in smokers.

Reference range

<100 mIU/L

Sample & container required SST (gold top) preferred, serum (red top) accepted
Sample volume 1 mL
Transport storage Store at 2-8°C and send by first class post. If sample receipt will be delayed by >3 days, store samples at -20°C and send frozen
Turnaround time 4 weeks
Notes

Samples with total ALP activity >800 IU/L may react non-specifically in the PLAP assay.

Innotest enzyme immunoassay